Literature DB >> 1363274

Establishment of cytotoxic CD4+ T cell clones from cancer patients treated by local immunotherapy.

H Nagaoka1, T Monden, I Sakita, Y Katsumoto, T Wakasugi, Y Kawasaki, N Tomita, T Takeda, T Yagyu, H Morimoto.   

Abstract

We have previously reported that the antitumor effect of OK-432, a Streptococcal preparation, is markedly augmented when injected intratumorally together with fibrinogen (Cancer, 69: 636-642, 1992). In order to elucidate the mechanism of the antitumor effects, we established T cell clones from regional lymph nodes of colorectal cancer patients who received this local immunotherapy. By culture of lymph node lymphocytes, in the presence of IL-2 and OK-432, 4 clones of T cells were established from 4 patients treated by local immunotherapy. These clones had a helper T cell phenotype (CD3+, CD4+, CD8-, CD56-, WT31+) and were successfully maintained for several months. The cells strongly expressed CD25 when stimulated with OK-432 and exhibited a high level of cytotoxic activity in part explained by the increased expression of ICAM-1 and LFA-1, and the release of TNF beta. These results suggest that the CD4+ T cells play a role in the antitumor mechanism of local immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363274     DOI: 10.1007/bf02179041

Source DB:  PubMed          Journal:  Biotherapy        ISSN: 0921-299X


  2 in total

1.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.

Authors:  Y Katsumoto; T Monden; T Takeda; A Haba; Y Ito; E Wakasugi; T Wakasugi; M Sekimoto; T Kobayashi; H Shiozaki; T Shimano; M Monden
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

2.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.

Authors:  Y Yamaguchi; E Miyahara; A Ohshita; Y Kawabuchi; K Ohta; K Shimizu; K Minami; J Hihara; A Sawamura; T Toge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.